Valuation: Arvinas, Inc.

Market Cap 48Cr 42Cr 40Cr 36Cr 68Cr 4.61TCr 68Cr 476.89Cr 185.48Cr 2.35TCr 179.41Cr 175.56Cr 7.56TCr P/E 2026 *
-325x
P/E 2027 * -2.1x
Enterprise Value 2.72Cr 2.42Cr 2.26Cr 2.05Cr 3.87Cr 262.52Cr 3.9Cr 27Cr 11Cr 133.92Cr 10Cr 10Cr 430.52Cr EV / Sales 2026 *
0.09x
EV / Sales 2027 * 2.67x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day-1.03%
1 week-2.53%
Current month-5.49%
1 month-22.15%
3 months-13.49%
6 months-34.85%
Current year-38.36%
1 week 7.22
Extreme 7.22
7.82
1 month 7.22
Extreme 7.22
9.34
Current year 6.97
Extreme 6.97
14.51
1 year 6.97
Extreme 6.97
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 12/02/2026
Director of Finance/CFO 56 24/06/2024
Chief Tech/Sci/R&D Officer 58 17/06/2024
Director TitleAgeSince
Chairman 66 15/06/2023
Director/Board Member 64 01/07/2018
Chairman 67 12/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/05/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/05/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%-2.53%-24.01%-61.71% 48Cr
+4.16%+4.16%+49.37%+94.17% 7.47TCr
-0.07%-1.37%+23.00%+78.84% 5.88TCr
-0.43%+0.38%+6.89%+34.59% 4.84TCr
-1.48%-2.25%+329.09%+698.20% 4.28TCr
-0.91%-3.35%+26.81%+30.88% 4.28TCr
-0.43%-0.68%+5.30%+108.64% 4.12TCr
-0.11%+1.96%+9.19%+52.66% 3.11TCr
-2.07%+1.16%+35.00%+26.28% 3.03TCr
-0.76%-2.88%-8.97%-13.92% 2.4TCr
Average -0.28%-0.48%+45.17%+104.86% 3.95TCr
Weighted average by Cap. +0.28%-0.54%+55.62%+129.52%

Financials

2026 *2027 *
Net sales 30Cr 26Cr 25Cr 22Cr 42Cr 2.85TCr 42Cr 295.43Cr 114.91Cr 1.46TCr 111.14Cr 108.76Cr 4.68TCr 6.42Cr 5.7Cr 5.33Cr 4.83Cr 9.13Cr 618.81Cr 9.19Cr 64Cr 25Cr 315.68Cr 24Cr 24Cr 1.01TCr
Net income -7L -6L -6L -5L -9L -6.42Cr -10L -66.49L -25.86L -3.28Cr -25.01L -24.48L -11Cr -25Cr -22Cr -21Cr -19Cr -35Cr -2.39TCr -35Cr -247.29Cr -96Cr -1.22TCr -93Cr -91Cr -3.92TCr
Net Debt -45Cr -40Cr -37Cr -34Cr -64Cr -4.35TCr -65Cr -449.72Cr -174.91Cr -2.22TCr -169.19Cr -165.56Cr -7.13TCr -31Cr -27Cr -25Cr -23Cr -44Cr -2.96TCr -44Cr -306.13Cr -119.07Cr -1.51TCr -115.17Cr -112.7Cr -4.85TCr
Projected Income Statement - Annual - Arvinas, Inc.
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
07/26/07 $7.310 -2.01% 5,85,799
05/26/05 $7.460 +0.67% 6,28,531
02/26/02 $7.410 -0.27% 5,85,123
01/26/01 $7.430 -3.94% 8,07,321
30/26/30 $7.735 +3.13% 10,61,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Arvinas, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.310USD
Average target price
13.93USD
Spread / Average Target
+90.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arvinas, Inc.
  1. Stock Market
  2. Stocks
  3. ARVN Stock